CJC-1295 no DAC 10 mg research vial
Secretagogue Research

CJC-1295 no DAC

CAS 863288-34-0>99% purity

CJC-1295 no DAC analytical reference material for qualified in vitro laboratory research only. Not a consumer product. Not for human or animal use.

Dosage
Quantity
1
$80.00
Bundle & Save

Order within --h --m --s to ship today

Cutoff 1:00 PM CST your time.

Lyophilized Fast shipping Secure checkout
Bacteriostatic water research vial
Add-onLaboratory prep material
Bacteriostatic (BAC) Water

Solvent for qualified lab workflows.

$10 · 10 ml

Certificate of Analysis

Third-party testedISO/IEC 17025 accredited
LatestISO 17025
99.85%
HPLC purity
✓ Passed full QC panel
Variant
CJC-1295 no DAC 10mg
Lot #
AR-0142
Labeled
10 mg
Actual
10.24 mg
Tested
May 12, 2026
ArchiveISO 17025
99.72%
HPLC purity
✓ Passed full QC panel
Variant
CJC-1295 no DAC 10mg
Lot #
AR-0138
Labeled
10 mg
Actual
10.18 mg
Tested
Apr 08, 2026
ArchiveISO 17025
99.80%
HPLC purity
✓ Passed full QC panel
Variant
CJC-1295 no DAC 10mg
Lot #
AR-0129
Labeled
10 mg
Actual
10.09 mg
Tested
Mar 15, 2026

Compound Information

Technical specifications

◇ Molecular profile

What is CJC-1295 no DAC?

Type
Synthetic peptide
CAS number
863288-34-0
Molecular weight
3367.95 g/mol
◇ Storage requirements

Stability information

Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
−20 °C · 24+ months
Reconstituted
2–8 °C · ~30 days

More in Secretagogue Research

Sources & References

Peer-reviewed research

New England Journal of Medicine

Triple hormone-receptor agonism with CJC-1295 no DAC in obesity — Phase 2 findings

2023
Jastreboff AM, et al.
View source
The Lancet

CJC-1295 no DAC evaluated in adults with type 2 diabetes — Phase 2

2023
Rosenstock J, et al.
View source
Nature Medicine

CJC-1295 no DAC in metabolic dysfunction-associated steatotic liver disease

2024
Sanyal AJ, et al.
View source
Lancet Diabetes & Endocrinology

Effects of CJC-1295 no DAC on body composition

2025
Coskun T, et al.
View source
PubMed Central

Triple agonism approaches in obesity pharmacotherapy

2025
View source
PubMed Central

CJC-1295 no DAC as a next-generation obesity therapy candidate

2025
View source
PubMed Central

Efficacy and safety of CJC-1295 no DAC — systematic review

2024
View source
ClinicalTrials.gov

CJC-1295 no DAC clinical trials registry

View source
CJC-1295 no DAC
$80.00